NEW YORK (GenomeWeb News) – Veracyte said after the close of the market on Monday that Cigna has issued a positive coverage decision for the Afirma Gene Expression Classifier test.

The decision means that about 13 million Cigna customers will have access to Veracyte's thyroid cancer test as a covered benefit. Cigna's policy takes effect immediately, Veracyte said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.